Welcome to LookChem.com Sign In|Join Free

CAS

  • or

69-09-0

Post Buying Request

69-09-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

69-09-0 Usage

Chemical Properties

Crystalline Solid

Originator

Thorazine, SKF, US ,1954

Uses

Different sources of media describe the Uses of 69-09-0 differently. You can refer to the following data:
1. Chlorpromazine hydrochloride is used in the treatment of schizophrenia; anti-emetic; as an antipsychotic in pills, injections, and suppositories; to relieve nausea and vomiting associated with malignant diseases. In veterinary medicine, it is used as an anti-emetic, tranquilizer and sedative. It has slight antihistaminic and anti adrenaline actions. It is a peripheral vasodilator and adepressant that blocks dopamine receptors in the central nervous system.
2. Antiemetic;Dopamine antagonist
3. Used as an Antiemetic, Antipsychotic

Definition

ChEBI: The hydrochloride salt of chlorpromazine.

Manufacturing Process

To a boiling suspension of 11.6 g of chlorophenothiazine (consisting of a mixture of two isomers melting at 196° to 198°C and 116° to 117°C, respectively, the latter in minor proportion) and 2.4 g of sodium amide (80%) in 60 cc of xylene, there are added over a period of one hour 7.5 g of 3-dimethylamino-1-chloropropane in solution in its own weight of xylene. At the end of the addition, heating is continued for one hour under reflux. After cooling, the contents are taken up in acidified water and the xylene separated. The aqueous layer is made strongly alkaline by means of sodium hydroxide in order to liberate the base and this is extracted with ether. On distillation of the ethereal extract there is obtained 10-(3'-dimethylamino-propyl)- chlorophenothiazine which distills at 200° to 205°C under a pressure of 0.8 mm Hg. Its hydrochloride, recrystallized from chlorobenzene, melts at 177° to 178°C. The chlorophenothiazine may be prepared by reacting mchlorodiphenylamine with sulfur in the presence of an iodine catalyst.

Therapeutic Function

Tranquilizer

General Description

Different sources of media describe the General Description of 69-09-0 differently. You can refer to the following data:
1. Chlorpromazinehydrochloride, 2-chloro-10-[3-(dimethylamino)propyl]phenothiazine monohydrochloride (Thorazine), was the first phenothiazinecompound introduced into therapy. It is still usefulas an antipsychotic. Other uses are in nausea, vomiting, andhiccough. Oral doses of chlorpromazine and thioridazinehave systemic availability of 25% to 35% because of significantfirst-pass metabolism. Chlorpromazine and other phenothiazinesare metabolized extensively by CYP2D6. In contrast, bioavailability of chlorpromazine may beincreased up to 10-fold with injections, but the clinical doseusually is decreased by only threefold to fourfold.Chlorpromazine may weakly induce its own hepatic metabolism,because its concentration in blood is lower after severalweeks of treatment at the same dosage. Alterations of GImotility also may contribute. The drug has significant sedativeand hypotensive properties, possibly reflecting centralhistaminergic and peripheral α1-noradrenergic blockingactivity, respectively. Effects of peripheral anticholinergic activityare common. As with the other phenothiazines, the effectsof other CNS-depressant drugs, such as sedatives andanesthetics, can be potentiated.
2. White or creamy-white odorless crystalline powder with very bitter taste. pH (5% aqueous solution) 4.0-5.5. pH (10% aqueous solution) 4-5.

Air & Water Reactions

Decomposes on exposure to air and light. becoming yellow, pink and, finally, violet. Water soluble.

Reactivity Profile

Chlorpromazine hydrochloride is incompatible in aqueous solution with sodium salts of barbiturates and other alkaline solutions. Solutions may be stabilized by addition of antioxidants and storing under nitrogen.

Fire Hazard

Flash point data for Chlorpromazine hydrochloride are not available; however, Chlorpromazine hydrochloride is probably combustible.

Biological Activity

dopamine receptors are a class of g protein-coupled receptors that are prominent in the central nervous system. dopamine receptors are implicated in many neurological processes. thus, dopamine receptors are common neurologic drug targets. antipsychotics are often dopamine receptor antagonists while typically psychostimulants are indirect agonists of dopamine receptors. chlorpromazine is a dopamine antagonist.

Biochem/physiol Actions

Chlorpromazine demonstrates cytotoxic and antiproliferative activity against leukemic cells, but does not affect the viability of normal lymphocytes.

Clinical Use

#N/A

Safety Profile

Poison by ingestion, intraperitoneal, intravenous, and subcutaneous routes. An experimentalteratogen. Experimental reproductive effects. An anti-emetic and antipsychotic drug. Human systemic effects: anorexia (human), excitement, gastrointestinal changes, irritability, pulse rate increase, respiratory stimulation, rigidity, somnolence, sweating. Mutation data reported. When heated to decomposition it emits very toxic fumes of Cl-, NOx, and SOx.

Veterinary Drugs and Treatments

The clinical use of chlorpromazine as a neuroleptic agent has diminished, but the drug is still used for its antiemetic effects in small animals and occasionally as a preoperative medication and tranquilizer. As an antiemetic, chlorpromazine will inhibit apomorphineinduced emesis in the dog but not the cat. It will also inhibit the emetic effects of morphine in the dog. It does not inhibit emesis caused by copper sulfate, or digitalis glycosides. Once the principle phenothiazine used in veterinary medicine, chlorpromazine has been largely supplanted by acepromazine. It has similar pharmacologic activities as acepromazine, but is less potent and has a longer duration of action. For further information, refer to the acepromazine monograph.

in vitro

the antipsychotic activity of chlorpromazine has been associated with its ability to act as a dopamine-receptor antagonist. the manner in which chlorpromazine, with its phenothiazine ring structure, interacted with a receptor for dopamine. furthermore, chlorpromazine inhibited the binding of [3h]spiperone, and the inhibition curve was consistent with a single class of binding sites [1].

in vivo

daily administration of chlorpromazine to rats for 21 days induced catalepsy, tolerance to catalepsy and locomotor sensitization following pcp challenge. results suggest that daily chlorpromazine treatment induced da/nmda-receptor sensitization to total locomotor activity following pcp challenge [2].

Drug interactions

Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone. Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval and disopyramide; avoid with amiodarone and dronedarone. Antibacterials: increased risk of ventricular arrhythmias with delamanid, moxifloxacin and telithromycin - avoid with moxifloxacin. Antidepressants: increased level of tricyclics, possibly increased risk of ventricular arrhythmias and antimuscarinic side effects; increased risk of ventricular arrhythmias with citalopram and escitalopram - avoid; increased risk of convulsions with vortioxetine. Anticonvulsants: antagonises anticonvulsant effect; concentration of fosphenytoin and phenytoin possibly increased or decreased; concentration of both drugs reduced with phenobarbital. Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol. Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide - avoid; concentration of haloperidol possibly increased; possible increased risk of ventricular arrhythmias with risperidone. Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir - avoid. Anxiolytics and hypnotics: increased sedative effects. Atomoxetine: increased risk of ventricular arrhythmias.Beta-blockers: enhanced hypotensive effect; concentration of both drugs may increase with propranolol; increased risk of ventricular arrhythmias with sotalol. Cytotoxics: increased risk of ventricular arrhythmias with vandetanib - avoid; increased risk of ventricular arrhythmias with arsenic trioxide. Diuretics: enhanced hypotensive effect. Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity. Pentamidine: increased risk of ventricular arrhythmias. Ulcer-healing drugs: effects enhanced by cimetidine.

Metabolism

Chlorpromazine is subject to considerable first-pass metabolism in the gut wall and is also extensively metabolised in the liver. Paths of metabolism of chlorpromazine include hydroxylation and conjugation with glucuronic acid, N-oxidation, oxidation of a sulfur atom, and dealkylation.Chlorpromazine is excreted in the urine and bile in the form of both active and inactive metabolites; there is some evidence of enterohepatic recycling.

references

[1] harrold mw, chang ya, wallace ra, farooqui t, wallace lj, uretsky n, miller dd. charged analogues of chlorpromazine as dopamine antagonists. j med chem. 1987 sep;30(9):1631-5.[2] nsimba se. effects of daily chlorpromazine administration on behavioural and physiological parameters in the rat. indian j physiol pharmacol. 2009 jul-sep;53(3):209-18.

Check Digit Verification of cas no

The CAS Registry Mumber 69-09-0 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 69-09:
(4*6)+(3*9)+(2*0)+(1*9)=60
60 % 10 = 0
So 69-09-0 is a valid CAS Registry Number.
InChI:InChI=1/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H

69-09-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2481)  Chlorpromazine Hydrochloride  >98.0%(HPLC)(T)

  • 69-09-0

  • 5g

  • 390.00CNY

  • Detail
  • TCI America

  • (C2481)  Chlorpromazine Hydrochloride  >98.0%(HPLC)(T)

  • 69-09-0

  • 25g

  • 990.00CNY

  • Detail
  • Sigma-Aldrich

  • (C1900000)  Chlorpromazinehydrochloride  European Pharmacopoeia (EP) Reference Standard

  • 69-09-0

  • C1900000

  • 1,880.19CNY

  • Detail
  • USP

  • (1125006)  Chlorpromazinehydrochloride  United States Pharmacopeia (USP) Reference Standard

  • 69-09-0

  • 1125006-200MG

  • 4,662.45CNY

  • Detail
  • Sigma-Aldrich

  • (31679)  Chlorpromazinehydrochloride  VETRANAL, analytical standard

  • 69-09-0

  • 31679-250MG

  • 404.82CNY

  • Detail
  • Cerilliant

  • (C-904)  Chlorpromazinehydrochloridesolution  1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material

  • 69-09-0

  • C-904-1ML

  • 263.25CNY

  • Detail

69-09-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name chlorpromazine hydrochloride

1.2 Other means of identification

Product number -
Other names 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, monohydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:69-09-0 SDS

69-09-0Synthetic route

2-chlorophenothiazine
92-39-7

2-chlorophenothiazine

3-(dimethylamino)propyl chloride hydrochloride
5407-04-5

3-(dimethylamino)propyl chloride hydrochloride

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

Conditions
ConditionsYield
With potassium hydroxide; Aliquat 336 at 80℃; for 1h;85%
oxovanadium(IV) sulfate

oxovanadium(IV) sulfate

chloropromazine cation radical
50-53-3

chloropromazine cation radical

A

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

B

vanadium(5+)

vanadium(5+)

Conditions
ConditionsYield
In water Kinetics; deoxygenated solutions, 25.0-38.7°C, 0.1 to 1.0 M - H(1+); not isolated, detd. by stopped-flow UV/VIS spectroscopy;
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

chlorpromazine sulfoxide
969-99-3

chlorpromazine sulfoxide

Conditions
ConditionsYield
With oxygen; nitrogen(II) oxide In acetonitrile for 2h; -20 deg C -> room temperature;100%
With oxygen In acetonitrile for 2h; Product distribution; -20 deg C -> room temperature; aerial oxidation of various phenothiazines and related compounds catalysed by nitrogen oxides, possible mechanism, intermediate cation radicals;100%
With ethanol; dihydrogen peroxide
water
7732-18-5

water

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

potassium hexacyanoferrate(III)

potassium hexacyanoferrate(III)

chlorpromazinium ferricyanide monohydrate

chlorpromazinium ferricyanide monohydrate

Conditions
ConditionsYield
In water E-2 M solns. were mixed; ppt. was filtered, thoroughly washed with distd. water, dried at room temp., elem. anal.;99.5%
ammonium tetrathiocyanodiamminochromate(III) monohydrate

ammonium tetrathiocyanodiamminochromate(III) monohydrate

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

chlorpromazinium reineckate

chlorpromazinium reineckate

Conditions
ConditionsYield
In water E-2 M solns. were mixed; ppt. was filtered, thoroughly washed with distd. water, dried at room temp., elem. anal.;99.5%
sodium hexanitro cobaltate(III)

sodium hexanitro cobaltate(III)

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

chlorpromazinium cobaltnitrite

chlorpromazinium cobaltnitrite

Conditions
ConditionsYield
In water E-2 M solns. were mixed; ppt. was filtered, thoroughly washed with distd. water, dried at room temp., elem. anal.;99.5%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

methyl iodide
74-88-4

methyl iodide

SKF 2680J
362-02-7

SKF 2680J

Conditions
ConditionsYield
Stage #1: chlorpromazine hydrochloride With sodium hydroxide In diethyl ether
Stage #2: methyl iodide In acetonitrile Reflux; Darkness;
99%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

chloropromazine radical cation

chloropromazine radical cation

Conditions
ConditionsYield
With potassium thioacyanate In water Rate constant; Ambient temperature; with different oxidizing agents, salt concentration, and various pH range;97%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

2-chloro-10-(3-dimethylaminopropyl)phenothiazine 5-oxide hydrochloride
316-07-4

2-chloro-10-(3-dimethylaminopropyl)phenothiazine 5-oxide hydrochloride

Conditions
ConditionsYield
With dihydrogen peroxide In ethanol a) RT, overnight, b) reflux, 2 h;95.5%
With hydrogenchloride; potassium metaperiodate In water Ambient temperature;
With n-C4F9; perfluoro-cis-2,3-dialkyloxaziridine; n-C3F7 In various solvent(s) at -40℃; for 0.5h; Yield given;
ethyl bromide
74-96-4

ethyl bromide

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

3-(2-chloro-10H-phenothiazin-10-yl)-N-ethyl-N,N-dimethylpropan-1-aminium bromide
153871-17-1

3-(2-chloro-10H-phenothiazin-10-yl)-N-ethyl-N,N-dimethylpropan-1-aminium bromide

Conditions
ConditionsYield
Stage #1: chlorpromazine hydrochloride With sodium hydroxide In diethyl ether
Stage #2: ethyl bromide In acetonitrile Reflux; Darkness;
93%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

zinc(II) chloride
7646-85-7

zinc(II) chloride

Zn(C6H4SN((CH2)3NH(CH3)2)C6H3Cl)4Cl2(4+)*4Cl(1-)=[Zn(C6H4SN((CH2)3NH(CH3)2)C6H3Cl)4Cl2]Cl4

Zn(C6H4SN((CH2)3NH(CH3)2)C6H3Cl)4Cl2(4+)*4Cl(1-)=[Zn(C6H4SN((CH2)3NH(CH3)2)C6H3Cl)4Cl2]Cl4

Conditions
ConditionsYield
In water slow addn. of soln. of ZnCl2 to soln. of ligand with stirring, stirring (room temp., 3 h), conctg., cooling; decanting viscous liq., redissolving in methanol with stirring at 60°C, suction filtn., washing (2-3 times, cold methanol), drying (air),drying (vac.), recrystn. (hot methanol), elem. anal.;92.5%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

bis(trifluoromethane)sulfonimide lithium
90076-65-6

bis(trifluoromethane)sulfonimide lithium

C2HF6NO4S2*C17H19ClN2S
1309962-25-1

C2HF6NO4S2*C17H19ClN2S

Conditions
ConditionsYield
With water at 20℃; for 2h;91%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

2-deuterio-10-[3-(dimethylamino)-1-propyl]phenothiazine

2-deuterio-10-[3-(dimethylamino)-1-propyl]phenothiazine

Conditions
ConditionsYield
With bis(η3-allyl-μ-chloropalladium(II)); 1-deuteriodiphenylmethanol; 3-(2,6-dibenzhydryl-4-methylphenyl)-4,5-dimethyl-1-(2,4,6-trimethylbenzyl)imidazolium chloride; caesium carbonate In toluene at 90℃; for 16h; Inert atmosphere;90%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

potassium vinyltrifluoroborate

potassium vinyltrifluoroborate

N,N-dimethyl-3-(2-vinyl-10H-phenothiazin-10-yl)propan-1-amine

N,N-dimethyl-3-(2-vinyl-10H-phenothiazin-10-yl)propan-1-amine

Conditions
ConditionsYield
With dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane; palladium diacetate; potassium carbonate In 1,4-dioxane; water at 90℃; for 2h; Schlenk technique; Inert atmosphere;81%
hexaammonium heptamolybdate tetrahydrate

hexaammonium heptamolybdate tetrahydrate

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

Mo2O4(C6H4SN(CH2)3N(CH3)2C6H3Cl)2(H2O)2

Mo2O4(C6H4SN(CH2)3N(CH3)2C6H3Cl)2(H2O)2

Conditions
ConditionsYield
In hydrogenchloride (NH4)6Mo7O24*4H2O in 2 M HCl was added to soln. of ligand in water with vigorous stirring, suspn. set aside for 2 h; suspn. filtered, washed with water, ethanol and dried in vacuo over fused CaCl2; elem. anal.;76%
yttrium(III) nitrate
13494-98-9

yttrium(III) nitrate

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

Y(3+)*2C17H19N2SCl*3NO3(1-) = [Y(C17H19N2SCl)2(NO3)2](NO3)

Y(3+)*2C17H19N2SCl*3NO3(1-) = [Y(C17H19N2SCl)2(NO3)2](NO3)

Conditions
ConditionsYield
In water warming (60°C, 30 min); washing (water, Et2O), drying (vac.); elem. anal.;70%
potassium hexachloropalatinate(IV)

potassium hexachloropalatinate(IV)

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

chlorpromazine chlorpromazinehydrochloridepentachloridoplatinate(IV)

chlorpromazine chlorpromazinehydrochloridepentachloridoplatinate(IV)

Conditions
ConditionsYield
In water at 20℃; Darkness;65.69%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

promazine
58-40-2

promazine

Conditions
ConditionsYield
In water Irradiation; in micelles with detergent Brij 58 in presence of 2,5-dimethylfurane;56%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

uranyl(VI) acetate dihydrate

uranyl(VI) acetate dihydrate

UO2(CH3COO)2(C6H4SN(CH2CH2CH2N(CH3)2)C6H3Cl)(H2O)2

UO2(CH3COO)2(C6H4SN(CH2CH2CH2N(CH3)2)C6H3Cl)(H2O)2

Conditions
ConditionsYield
In water soln. refluxed for 6 h; cooling under ice-cold water for 4 d; ppt. filtered and dried in vac.; elem. anal.;50%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

A

10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-ol
3926-64-5

10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-ol

B

promazine
58-40-2

promazine

Conditions
ConditionsYield
In water Irradiation;A 5%
B 38%
In water Product distribution; Irradiation; in micelles with several detergents, different atmospheres and reaction times;A 5%
B 38%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

palladium dichloride

palladium dichloride

Pd(C6H4SN(CH2CH2CH2NH(CH3)2)C6H3Cl)Cl3
75234-56-9, 82489-75-6

Pd(C6H4SN(CH2CH2CH2NH(CH3)2)C6H3Cl)Cl3

Conditions
ConditionsYield
In hydrogenchloride; water stirring (ambient temp., 1 h); pptn. on cooling (4°C), washing (water, MeOH), drying (vac.), recrystn. (MeOH); elem. anal.;37.8%
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

urea
57-13-6

urea

10-(3-(dimethylamino)propyl)-10H-phenothiazine-2-carbonitrile
7678-64-0

10-(3-(dimethylamino)propyl)-10H-phenothiazine-2-carbonitrile

Conditions
ConditionsYield
With nickel(II) acetylacetonate; potassium fluoride; phenylsilane; zinc; bis(2-diphenylphosphinoethyl)phenylphosphine In 1-methyl-pyrrolidin-2-one at 90 - 140℃; for 20h;37%
1,4-dibromo-butane
110-52-1

1,4-dibromo-butane

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

N,N'-bis-[3-(2-chloro-phenothiazin-10-yl)-propyl]-N,N,N',N'-tetramethyl-N,N'-butanediyl-di-ammonium; dibromide

N,N'-bis-[3-(2-chloro-phenothiazin-10-yl)-propyl]-N,N,N',N'-tetramethyl-N,N'-butanediyl-di-ammonium; dibromide

Conditions
ConditionsYield
With ethanol
8-Anilino-1-naphthalenesulfonic acid
82-76-8

8-Anilino-1-naphthalenesulfonic acid

chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

[3-(2-chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine; mono-(8-anilino-naphthalene-1-sulfonate)
71643-78-2

[3-(2-chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine; mono-(8-anilino-naphthalene-1-sulfonate)

Conditions
ConditionsYield
In water
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

C17H20ClN2S

C17H20ClN2S

Conditions
ConditionsYield
With potassium metaperiodate; phosphoric acid; sulfuric acid In water
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

glycerol
56-81-5

glycerol

promazine Hydrochloride
53-60-1

promazine Hydrochloride

Conditions
ConditionsYield
other matrices, also with 4-chlorophenylalanine ethylester, time of irradiation, analyte concentration, matrix selection and matrix additives, primary beam density on the beam-induced dehalogenation in liquid secondary ion mass spectroscopy;
chlorpromazine hydrochloride
69-09-0

chlorpromazine hydrochloride

methyl iodide
74-88-4

methyl iodide

methochlorpromazine iodide

methochlorpromazine iodide

Conditions
ConditionsYield
With sodium hydroxide 1) water; 2) acetone, 25 deg C, 1 h;

69-09-0Relevant articles and documents

Preparation method of chlorpromazine hydrochloride

-

Paragraph 0018; 0025-0051, (2021/09/26)

The invention relates to a preparation method of chlorpromazine hydrochloride, and belongs to the technical field of medicine preparation. According to the method, 2-chlorophenothiazine and N, N-dimethyl-3-chloropropylamine are used as raw materials, an N-methyl pyrrolidone organic solvent is adopted, chlorpromazine is generated under the action of a 4-dimethylaminopyridine catalyst, the obtained chlorpromazine and hydrogen chloride gas are salified, and chlorpromazine hydrochloride is obtained. According to the method, a toxic toluene reagent is not needed, and an N-methyl pyrrolidone organic solvent is adopted, so that the method is more environment-friendly, and is more beneficial to recovery of chlorpromazine, and the yield and purity of chlorpromazine are improved. A large amount of sodium hydroxide does not need to be added, sodium hydroxide and tetrabutylammonium bromide in an original process can be replaced by selecting 4-dimethylaminopyridine, and the yield and purity of chlorpromazine hydrochloride are remarkably improved. By controlling the conditions of the salt forming reaction of hydrochloric acid, the crystallization and purification of chlorpromazine hydrochloride are facilitated, and high-purity chlorpromazine hydrochloride can be obtained.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 69-09-0